

REFERENCES

1. Family planning program guidelines manual [Internet]. 2nd ed. Illinois Department of Human Services; 2008. Available from: <http://www.dhs.state.il.us>
2. World Health Organization, John Hopkins Bloomberg School of Public Health/Center for Communications Program. Family planning: a global handbook for providers 2011 update. Baltimore; 2011.
3. Decision-making tool for family planning clients and providers: a resource for high-quality counselling [Internet]. 1st ed. World Health Organization and Department of Reproductive Health and Research; 2005. Available from: http://www.who.int/reproductivehealth/publications/family_9241593229index/en/index.html
4. Medical and service delivery guidelines for sexual and reproductive health services [Internet]. 1st ed. International Planned Parenthood Federation; 2009. Available from: <https://www.k4health.org/toolkits/permanent-methods/medical-and-service-delivery-guidelines-sexual-and-reproductive-health>
5. Department of Health. Competency-based training manual on family planning. 2011.
6. Hatcher RA, Rinehart W, Blackburn R, Geller JS, Shelton JD. The essentials of contraceptive technology: a handbook for clinic staff [Internet]. 2003. Available from: http://apps.who.int/iris/bitstream/10665/42331/1/1885960018_eng.pdf?ua=1
7. Kim Y, Lettenmaier C. Tools to assess family planning counseling: observation and interview. 1995. Available from: http://pdf.usaid.gov/pdf_docs/pnacg547.pdf
8. World Health Organization. Medical eligibility criteria for contraceptive use: a WHO family planning cornerstone. 4th ed. Geneva: World Health Organization; 2010.
9. Centers for Disease Control and Prevention. U.S. selected practice recommendations for contraceptive use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd ed. 2012. Available from: <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6205a1.htm>
10. World Health Organization. Cardiovascular disease and steroid hormone contraception: report of a WHO scientific group. WHO Technical Report Series 877. Geneva, Switzerland: World Health Organization; 1998.
11. Hannaford PC, Owen-Smith V. Using epidemiological data to guide clinical practice: review of studies on cardiovascular disease and use of combined oral contraceptives. BMJ. 1998; 316(7136):984–87.
12. Vandenbroucke J, Rosing J, Bloemenkamp K, Middeldorp S, Helmerhorst F, Bouma B et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med. 2001;344(20):1527–35.
13. Vandenbroucke, Kovacs P. The risk of cardiovascular disease with second- and third-generation oral contraceptives. Medscape Women's Health. 2002.
14. Population Reports. Spring 2000;28(1):Series A No. 1.

15. Graham CA, Ramos R, Bancroft J, Maglaya C, Farley TMM. The effects of steroid contraceptives on the well-being and sexuality of women: a double blind placebo controlled two-center study of combined and progestogen only methods. *Contracept*. 1995;52:363–369.
16. Wang CC, Kreiss JK, Reilly M. Risk of HIV infection in oral contraceptive pill users: a meta-analysis. *J Acq Immune Defic Syndr*. 1999;21(1):51–58.
17. Stephenson JM. Systematic review of hormonal contraception and risk of HIV transmission: when to resist meta-analysis. *AIDS*. 1998;12(6):545–53.
18. Family Health International. Introduction to contraceptive methods: an overview, contraceptive technology series. Family Health International. Maximizing Access and Quality (MAQ), Volume I.
19. World Health Organization. Oral contraceptives and neoplasia. WHO Technical Report Series.
20. Brinton LA, Huggins GR, Lehman HF et al. Long-term use of oral contraceptives and risk of invasive cervical cancer. *Int J Canc*. 1986;38:339–344.
21. World Health Organization. Progress in human reproduction research. 1998. Series 46.
22. Family Health International. A summary of major studies on OC use covers ovarian and endometrial cancer, breast cancer, cervical cancer and cardiovascular disease. Network. 1996;16(4).
23. World Health Organization. Oral contraceptive pills and the risk of thromboembolism: progress in human reproduction. 1996;No. 39.
24. Audet MC, Moreau M, Koltun WD et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. *JAMA*. 2001;285(18):2347–54.
25. Dittrich R, Parker L, Rosen JB et al. Transdermal contraception: evaluation of three transdermal norelgestromin/ethynodiol doses in a randomized, multicenter, dose-response study. *Am J Obstet Gynecol*. 2002;186(1):15–20.
26. Hedon B, Helmerhorst FM, Cronje HS et al. Comparison of efficacy, cycle control, compliance and safety in users of a contraceptive patch vs an oral contraceptive. *Int J Gynaecol Obstet*. 2000;70(Suppl 1):78.
27. Archer DF, Bigriff A, Smallwood GH. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. *Fertil Steril*. 2002;77(2 Suppl 2):27–31.
28. Dieben TO, Roumen JME, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. *Obstet Gynecol*. 2002;100(3):585–93.
29. Roumen FJ, Apter D, Mulders TM et al. Efficacy, tolerability, and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethynodiol. *Hum Reprod*. 2001;16(3):469–75. Volume 22 No. 3. Network. 2003.
30. World Health Organization Task Force on Oral Contraceptives. Effects of hormonal contraceptives on milk volume and infant growth. *Contracept*. 1984;30(6):505–521.
31. Dahlman T, Helgren M, Blomback M. Changes in blood coagulation and fibrinolysis in the normal puerperium. *Gynecol Obstet Invest*. 1985;20(1):37–44.
32. World Health Organization. Facts about once-a-month injectable contraceptives:

- memorandum from a WHO meeting. *Bulletin of the World Health Organization*. 1993;70(6):677–689.
33. Giwa-Osagie, WHO Task Force on Long-Acting Systemic Agents for Fertility Regulation. Metabolic effects of once-a-month injectable contraceptives. *Contracept*. 1994;49(5):121–134.
 34. International Medical Advisory Panel (IMAP). Statement on injectable contraceptive. *IPPF Medical Bulletin*. 1999 April;33(2).
 35. Fraser IS. Vaginal bleeding patterns in women using once-a-month injectable contraceptives. *Contracept*. 1994 Apr;49:399–420.
 36. World Health Organization. WHO updates on selected practice recommendations. 2008.
 37. Centers for Disease Control and Prevention. US medical eligibility criteria. 2012.
 38. Clinical practice guidelines on family planning. 2012 Nov. 1st ed.
 39. World Health Organization. Medical eligibility criteria for contraceptive use. Geneva: World Health Organization; 2000.
 40. World Health Organization. Medical eligibility criteria for contraceptive use. Geneva: World Health Organization; 1991.
 41. Fisher WA, Amanda B. Contraception in Canada: a review of method choices, characteristics, adherence and approaches to counseling. *CMAJ*. 2007;176(7):953–61.
 42. Blumenthal PD, Edelman A. Hormonal contraception. *Obstet Gynecol*. 2008;112:670–84.
 43. World Health Organization. Progestogen-only contraceptive use during lactation and its effects on the neonate statement. 2009.
 44. World Health Organization. Selected practice recommendations for contraceptive use. 2008 update.
 45. Amy J, Tripathi V. Contraception for women: an evidence based overview. *BMJ* [Internet]. 2009;339. Available from: <http://dx.doi.org/10.1136/bmj.b2895>
 46. Trussell J. Contraceptive efficacy. In: Hatcher R, editor. *Contracept Technol*. 18th ed. 2011.
 47. Grimes D, Lopez L, O'Brien P, Raymond E. Progestin-only pills for contraception. *Cochrane Database Syst Rev*. 2011;7.
 48. American College of Obstetricians and Gynecologists. Long-acting reversible contraceptives. *Practice Bulletin No. 121*. 2011 July;118(1).
 49. Merck Sharp and Dohme. Desogestrel (Cerazette) product information insert. 2011. Available from: <http://www.medsafe.govt.nz/profs/datasheet/c/Cerazettetab.pdf>
 50. Merck Sharp and Dohme. Exluton product information insert. 2010. Available from: <http://apps.who.int/prequal/whopar/whoparproducts/RH021part3v1.pdf>
 51. MIMS Philippines. Daphne product information insert. Available from: <http://www.mims.com/philippines/drug/info/Daphne/>
 52. Options Clinic. Medroxyprogesterone acetate (DMPA) product information insert. 2013. Available from: <http://www.optionsclinic.org/downloads/Depo-Provera.pdf>
 53. MIMS Philippines. Lyndavel product information insert. Available from: <http://www.mims.com/Philippines/drug/info/Lyndavel/?type=brief>
 54. Bayer. Noristerat product information insert. 2014. Available from: <http://www.medicines.org.uk/emc/medicine/1835/SPC>
 55. Merck Sharp and Dohme. Implanon implant. 2012. Available from: <http://www.medsafe.govt.nz/profs/datasheet/i/Implanonimplant.pdf>

56. Merck Sharp and Dohme. Implanon NXT implant. 2012. Available from: <http://www.medsafe.govt.nz/profs/datasheet/i/implanonNXTimplant.pdf>
57. Department of Health. Service providers' training for single-rod subdermal hormonal implant learner's manual. Manila, Philippines; 2013.
58. INFO Project. Insertion and removal of the new implants. Johns Hopkins Bloomberg School of Public Health; 2007.
59. World Health Organization. Medical eligibility criteria for contraceptive use: a WHO family planning cornerstone. 4th ed. Geneva: World Health Organization; 2009.
60. Kapp N, Curtis K. Intrauterine device insertion during the postpartum period: a systematic review. *Contracept*. 2009;80(4):327–36.
61. JHPIEGO. Postplacental intrauterine contraception device services. Maryland, USA; 2010.
62. Grimes D, Lopez L, Schulz K, Stanwood N. Immediate postabortal insertion of intrauterine devices. *Cochrane Database Syst Rev*. 2010.
63. Grimes D, Lopez L, Schulz K, Van Vliet H, Stanwood N. Immediate post-partum insertion of intrauterine devices. *Cochrane Database Syst Rev*. 2010.
64. Hatcher RA, Rinehart W, Blackburn R, Geller JS, Shelton JD. The essentials of contraceptive technology: a handbook for clinic staff. Population Information Program, Johns Hopkins School of Public Health. Baltimore; 2003 Mar.
65. Department of Health. Family planning clinical standard. Manila: PFPP, Family Planning Service; 2014. Chapter 4, Condoms and non-program methods.
66. World Health Organization. Family planning: a global handbook for providers. 2008.
67. Department of Health. The Philippine clinical standards manual on family planning. Manila, Philippines; 2006.
68. Van der Wijden C, Brown J, Kleijnen J. Lactational amenorrhea for family planning. *Cochrane Database of Syst Rev [Internet]*. 2003; Available from: <http://dx.doi.org/10.1002/14651858.cd001329>
69. UK medical eligibility criteria for contraceptive use [Internet]. Faculty of Sexual and Reproductive Healthcare; 2009. Available from: <http://www.fsrh.org/pdfs/UKMEC2009.pdf>
70. Arévalo M, Jennings V, Sinai I. Efficacy of a new method of family planning: the standard days method. *Contracept*. 2002;65(5):333–338.
71. Population Council. Lactational amenorrhea method. 2012. Available from: http://www.popcouncil.org/uploads/pdfs/frontiers/Manuals/BCS/BCS_BrochureLAM.pdf
72. Ramos R, Kennedy K, Visness C. Effectiveness of lactational amenorrhoea in prevention of pregnancy in Manila, the Philippines: non-comparative prospective trial. *BMJ*. 1996;313(7062):909–912.
73. Gray R, Campbell O, Apelo R, Eslami S, Zácur H, Ramos R et al. Risk of ovulation during lactation. *Lancet*. 1990;335(8680):25–29.
74. Hatcher R, Trussell J, Stewart F, Nelson A, Kates W, Guest F et al. *Contraceptive technology*. 18th ed. New York; 2004.
75. Wilcox AJ, Dunson D, Baird DD. The timing of the “fertile window” in the menstrual cycle: day specific estimates from a prospective study. *BMJ*. 2000;321:1259–62.

76. Arevalo M, Sinai I, Jennings V. A fixed formula to define the fertile window of the menstrual cycle as the basis of a simple method of natural family planning. *Contracept*. 1999;60:357–60.
77. Spieler JM, Collins WP. Potential fertility-defining the window of opportunity. *J Int Med Res*. 2001;29 (Suppl 1);3A–13A.
78. World Health Organization. A prospective multicentre trial of the ovulation method of natural family planning II. The effectiveness phase. *Fertil Ster*. 1981;36:591–8.
79. Gray RH, Kambic RT, Lanctot CA, Martin MC, Wesley R, Cremins R. Evaluation of natural family planning programmes in Liberia and Zambia. *J Biosoc Sci*. 1993;25:249–58.
80. Wilcox AJ, Weinberg CR, Baird DD. Timing of sexual intercourse in relation to ovulation. *New Engl J Med*. 1995;333:1517–21.
81. World Health Organization, John Hopkins Bloomberg School of Public Health/Center for Communications Program. Family planning: a global handbook for providers 2011 update. Baltimore; 2011. Female sterilization; p. 165–182.
82. Bilateral tubal ligation by minilaparotomy under local anesthesia: participants' handbook. Department of Health, USAID; 2013. Preparation for surgery; p. 54–68.
83. Bilateral tubal ligation by minilaparotomy under local anesthesia: participants' handbook. Department of Health, USAID; 2013. The surgical procedure; p. 83–113.
84. [Internet]. 2014. Available from: [http://www.women.emedtv.com/laparoscopic-tubal-ligation-\(tbl\)- video](http://www.women.emedtv.com/laparoscopic-tubal-ligation-(tbl)- video)
85. ND M, SK C. Female sterilization: endoscopic methods. New Delhi India BI Churchill Livingstone 1992 [Internet]. 2014; Available from: <http://www.popline.org/node/323650>
86. Tubal ligation by culdoscopy. (Promotional material). Long Island City New York Weck (1977) 4 p [Internet]. 2014; Available from: <http://www.popline.org/node/499763>
87. World Health Organization. Medical eligibility criteria for contraceptive use: a WHO family planning cornerstone. 4th ed. Geneva: World Health Organization; 2009. Male sterilization; p. 105–106.
88. EngenderHealth. No-scalpel vasectomy. 1st ed. New York, N.Y.; 2003. p. 25–31.
89. World Health Organization, John Hopkins Bloomberg School of Public Health/Center for Communications Program. Family planning: a global handbook for providers 2011 update. Baltimore; 2011. Vasectomy; p. 183–198.
90. [Internet]. 2014. Available from: <http://www.buzzle.com/articles/types-of-vasectomy.htm>
91. Hatcher RA, Rinehart W, Blackburn R, Geller JS, Shelton JD. The essentials of contraceptive technology: a handbook for clinic staff. Baltimore: Population Information Program, Johns Hopkins Bloomberg School of Public Health; 2003 Mar. Chapter 10, Vasectomy.
92. Pollack AE et al. Female and male sterilization. In: Hatcher RA, editor. Contraceptive technology. 18th ed. 2011.
93. American Congress of Obstetrics and Gynecology. Practice Bulletin Number 46: Benefits and risks of Sterilization. *Obstet Gynecol*. 2003; 102(3): 647-658.

94. Pollack AE et al. Male and female sterilization. In: Hatcher RA et al., editors. Contraceptive technology. 18th ed. New York: Ardent Media; 2004. P. 531-573.
95. Hurskainen R, Hovi S, Gissler M, Grahn R, Kukkonen-Harjula K, Nord-Saari M, Mäkelä M. Hysteroscopic tubal sterilization: a systematic review of the Essure system. *Fertil Steril*. 2010;94(1):16-19. doi:10.1016/j.fertnstert.2009.02.080.
96. Miño M, Arjona JE, Cordón J, Pelegrin B, Povedano B, Chacon E. Success rate and patient satisfaction with the Essure sterilisation in an outpatient setting: a prospective study of 857 women. *Brit Jour Obstet Gynaec*. 2007 Jun;114(6):763-6.
97. National Statistics Office. Philippine teenage pregnancy in the last decade. 2010. Available from: <http://manilastandardtoday.com/2013/03/26/philippine-teenage-pregnancy-up-65-in-the-last-decade/>
98. American College of Obstetrics and Gynecology. Committee opinion no. 539: adolescents and long-acting reversible contraception: implants and intrauterine devices. *Obstet Gynecol*. 2012 Oct;120(4):983-8.
99. Barash P, Cullen B et.al. Handbook of clinical anesthesia. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins/Wolters Kluwer; 2013.
100. Wenk M, Weiss C, Möllmann M, Pöpping D. Procedural complications of spinal anaesthesia in the obese patient. *Anesthesiol Res Pract* [Internet]. 2012; Available from: <http://dx.doi.org/10.1155/2012/165267>
101. Edelman A MD, Kaneshiro B MD. Contraception counseling for obese women [Internet]. Uptodate. com. 2014. Available from: <http://www.uptodate.com/contents/contraception-counseling-for-obese-women>
102. Trussell J, Ellertson C, von Hertzen H, Bigrigg A, Webb A, Evans M et al. Estimating the effectiveness of emergency contraceptive pills. *Contracept*. 2003;67(4):259-265.
103. Irish Medicines Board. Summary of product characteristics (Norlevo) [Internet]. 2014 [4 December 2013]. Available from: http://www.imb.ie/images/uploaded/swedocuments/LicenseSPC_PA1166-001-001_01062012140100.pdf
104. Glasier A, Cameron S, Blithe D, Scherrer B, Mathe H, Levy D et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. *Contracept*. 2011;84(4):363-367.
105. Sivin I, Nash H, Waldman S. Jadelle® levonorgestrel rod implants: a summary of scientific data and lessons learned from programmatic experience. Population Council New York; 2002.
106. Bayer. Jadelle data sheet. 2010. Available from: <http://www.medsafe.govt.nz/profs/datasheet/j/Jadelleimplant.pdf>
107. Conde-Agudelo A, Belizan, J. Maternal morbidity and mortality associated with interpregnancy interval: cross sectional study. *BMJ*. 2000;321(7271):1255-1259.
108. Edmond K, Bhal R. Optimal feeding of low-birth weight infants. Technical Review. World Health Organization. 2006;1-130.
109. Malhotra N, Viswambaran L, Sundaram KR, Narayanan I. A controlled trial of

- alternative methods of oral feeding in neonates. *Early Hum Dev.* 1999 Feb;54(1):29–38.
110. Rocha N, Martinez F, Jorge S. Cup or bottle for preterm infants: effects on oxygen saturation, weight gain and breastfeeding. *J Hum Lact.* 2002;18:132–137.
111. Human Rights Watch. Reporting on gender-based violence: a guide for journalists. Human Rights News, hrw.org. 2006.
112. The National Women's Health Information Center, U.S. Department of Health and Human Services. Violence against women home. 2006. Available from: <http://www.womenhealth.gov>
113. Velzeboer M, Ellsberg M, Arcas CC, Moreno CG. Violence against women: the health sector responds (occasional publication no. 12). Pan American Health Organization; 2003. Chapter 1, Gender-based violence: a public health and human rights problem; p. 4–7.
114. Reyes L. Understanding the definition, framework, concepts and forms of gender-based violence. *Breaking barriers: a sourcebook on gender-based violence for obstetrics and gynecology.* 2nd ed. 2012;3:21–28.
115. McLean J, Kerr R, Varcoe C. Dealing with violence against women: health care responses. Moving towards change: strengthening the response of British Columbia's health care system to violence against women, a report to the Minister of Health and Minister Responsible for Seniors and the Minister of Women's Equality from the Minister's Advisory Council on Women's Health. 1999. p. 12–25.
116. World Health Organization. Violence against women information pack: a priority health issue. UN Declaration on Violence Against Women 1992, CEDAW (Recommendation No. 19, 1993); 1997 July. What health workers can do; p. 24–26.
117. Lentz GM, Lobo RA, Gershenson DM, Katz VL. Emotional aspects of gynecology: rape, incest and domestic violence. 6th ed. 2012;9:159–168.
118. Greenan L. Violence against women: a literature review. Edinburgh: Scottish Executive; 2004. Chapter 3.1.3, Socioeconomic consequences of violence against women; p. 28.
119. World Health Organization. Guidelines for medico-legal care for victims of sexual violence. 2003. Chapter 4, Assessment and examination of adult victims of sexual violence; p. 30–56.
120. Baram D. Sexuality, sexual dysfunction, and sexual assault. In: Novak E, Berek J, editor. *Novak's Gynecology*, Issue 935, Volume 2002. 13th ed. Lippincott Williams & Wilkins; 2002. p. 19.
121. Gardner G, Sewell C. *The Johns Hopkins manual of gynecology and obstetrics.* 2nd ed. Lippincott Williams & Wilkins; 2002. Chapter 29, Sexual assault and domestic violence; p. 35.
122. Centers for Disease Control and Prevention. Sexual assault and STDs. Sexually transmitted diseases treatment guidelines. *MMWR.* 2010;59(No. RR-12):90–95.
123. World Health Organization. Guidelines for medico-legal care for victims of sexual violence. 2003. Chapter 6, Treatment and follow-up care; p. 63–74.
124. World Health Organization, Department of Reproductive Health and Research

- (WHO/RHR), Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP), Knowledge for Health Project. Family planning: a global handbook for providers (2011 update). Baltimore and Geneva: CCP and WHO; 2011. Reproductive health issues: emergency contraceptive pills; 3:45–58.
125. Lentz GM, Lobo RA, Gershenson DM, Katz VL. Family planning: emergency contraception. 6th ed. 2012;13:256–257.
126. World Health Organization. Violence against women information pack: a priority health issue. UN Declaration on Violence Against Women 1992, CEDAW (Recommendation No. 19, 1993); 1997 July. Rape and sexual assault; p. 13.
127. Lentz G. Comprehensive gynecology. 5th ed. 2007. Chapter 10, Rape, incest, and domestic violence: discovery, management, counseling; p. 203–213.
128. World Health Organization. Medical eligibility for contraceptive use. 3rd ed. Geneva: World Health Organization; 2004.
129. World Health Organization, John Hopkins Bloomberg School of Public Health/Center for Communications Program. Family planning: a global handbook for providers 2011 update. Baltimore; 2011. Reproductive health issues: violence against women; 23:300–303.
130. World Health Organization. Community emergency preparedness: a manual for managers and policy makers [Internet]. Geneva: WHO; 1999 [25 February 2011]. Available from: <http://whqlibdoc.who.int/publications/9241545194.pdf>
131. Nour N. Maternal health considerations during disaster relief. Rev Obstet Gynecol. 2011;4(1):22– 27.
132. The Johns Hopkins and the International Federation of Red Cross and Red Crescent Societies. Public health guide for emergencies. Chapter 4, Reproductive health care; p. 136–197.
133. Inter-agency Working Group on Reproductive Health in Crises. Inter-agency field manual on reproductive health in humanitarian settings. 2010.
134. Committee on Health Care for Underserved Women. Committee opinion 457: preparing for disasters: perspectives on women. Washington, DC: American College of Obstetricians and Gynecologists; 2010.
135. Reproductive Health Sub-working Group of the ISDR/WHO Thematic Platform for Disaster Risk Management for Health. Integrating sexual and reproductive health into health emergency and disaster risk management. 2012 Oct.
136. World Health Organization, United Kingdom Health Protection Agency and Partners. Disaster risk management for health sexual and reproductive health. Global Platform. 2011 May;1–2.
137. International Federation of Gynecology and Obstetrics (FIGO) and International Consortium for Emergency Contraception (ICEC). Mechanism of action: How do levonorgestrel-only contraceptive pills (LNG ECPs) prevent pregnancy? London: International Federation of Gynecology and Obstetrics; 2011 Apr 4.
138. World Health Organization. Sexually transmitted infections (STIs) Fact Sheet N°110. 2013 Nov.
139. Sweet RL, Gibbs RS. Infectious diseases of the female genital tract. 5th ed. 2009. Chapter 5, Sexually transmitted diseases; p. 661.
140. World Health Organization. Global strategy for the prevention and control of sexually

transmitted infections: 2006-2015. Breaking the chain of transmission. 2007.

141. Faculty of Sexual and Reproductive Healthcare Clinical Guidance. Barrier methods for contraception and STI prevention. 2012 Aug.
142. World Health Organization, John Hopkins Bloomberg School of Public Health/Center for Communications Program. Family planning: a global handbook for providers 2011 update. Baltimore; 2011. Sexually transmitted infections, including HIV; 21:275–288.
143. Centers for Disease Control and Prevention. Clinical prevention and guidance. Sexually transmitted diseases treatment guidelines. MMWR. 2010;59(No. RR-12):2.
144. World Health Organization (WHO), United Nations Population Fund (UNFPA), Joint United Nations Programme on HIV/AIDS (UNAIDS). Condoms and HIV prevention (position statement 09). 2009. Available from: http://www.who.int/hiv/pub/condoms/20090318_position_condoms.pdf.
145. Centers for Disease Control and Prevention. Prevention methods: male condoms. Sexually transmitted diseases treatment guidelines. MMWR. 2010;59(No. RR-12):4–5.
146. Weller S, Davis K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev. 2002;(1):CD003255.
147. Manhart LE, Koutsky LA. Do condoms prevent genital HPV infection, external genital warts or cervical neoplasia? Sex Transm Dis. 2002;29:725–735.
148. French PP, Latka M, Gollub EL, Rogers C, Hoover DR, Stein ZA. Use-effectiveness of the female versus male condom in preventing sexually transmitted disease in women. Sex Transm Dis. 2003;30:433–439.
149. Fontanet AL, Saba J, Chandelying V, Sakondhavat C, Bhiraleus P, Rugpao S, et al. Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial. AIDS. 1998;12:1851– 1859.
150. Centers for Disease Control and Prevention. Prevention methods: cervical diaphragms. Sexually transmitted diseases treatment guidelines. MMWR. 2010;59(No. RR-12):5.
151. World Health Organization, John Hopkins Bloomberg School of Public Health/Center for Communications Program. Family planning: a global handbook for providers 2011 update. Baltimore; 2011. Lactation amenorrhea method; 19:259–266.
152. Neely JL, Abate M, Swinker M, D'Angio R. The effect of doxycycline on serum levels of ethinyl estradiol, norethindrone, and endogenous progesterone. Obstet Gynecol. 1991;77:416–420.
153. Dogterom P, van den Heuvel MW, Thomsen T. Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring Nuvaring with oral amoxicillin or doxycycline in two randomised trials. Clin Pharmacokinet. 2005;44:429–438.
154. Maggiolo F, Puricelli G, Dottorini M, Caprioli S, Bianchi W, Suter F. The effect of

- ciprofloxacin on oral contraceptive steroid treatments. *Drugs Exp Clin Res.* 1991;17:451–454.
155. Csemiczky G, Alvendal C, Landgren BM. Risk for ovulation in women taking a low-dose oral contraceptive (Microgynon) when receiving antibacterial treatment with fluoroquinolone (ofloxacin). *Adv Contracept.* 1996;12:101–109.
156. Periti P, Mazzei T, Mini E, Novelli A. Pharmacokinetic drug interactions of macrolides. *Clin Pharmacokinet.* 1992 Aug;23(2):106–31.
157. Nahata M. Drug interactions with azithromycin and the macrolides: an overview. *J Antimicrob Chemother.* 1996. 37(Suppl C):133–14.
158. Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit. Drug interactions with hormonal contraception (updated 2012 Jan). 2011 Jan.
159. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. *Lancet.* 1992;339:785–8.
160. Department of Health AO 2011-0005. Guidelines on ensuring quality standards in the delivery of FP program and services through compliance to ICV [Internet]. Available from: <http://www.rti.org/files/healthgov/ANNEX%20K1%20to%20K5.pdf>
161. Department of Health AO 2012-009. National strategy towards reducing unmet need for modern family planning as a means to achieving MDGs on maternal health [Internet]. Available from: <http://alfi.org.ph/wp-content/uploads/2012/07/Natl-Strategy-Toward-Reducing-Unmet-Need- DOH-AO-2012-0009-posted.pdf>
162. DOH. Family planning competency-based training: basic course handbook [Internet]. Available from: <http://www.rti.org/files/healthgov/FPCBT1%20Facilitator's%20Guide.pdf>
163. Department of Health. Fertility awareness: making a difference in the Philippine family planning program. 2002.
164. Family Health International. Checklists: provider checklists for reproductive health services. 2002. Available from: <http://www.fhi.org>